Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KARIM CHAMIE

Allopathic & Osteopathic Physicians Urology

NPI
1962478420
CMS profile
133967
Location
LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$120,518.62

91 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Janssen Biotech, Inc. $69,210.29 56
UROGEN PHARMA, INC. $23,249.72 9
Janssen Scientific Affairs, LLC $13,150.34 3
Astellas Pharma US Inc $5,853.34 7
AstraZeneca Pharmaceuticals LP $3,340.00 1
PFIZER INC. $2,795.14 4
Merck Sharp & Dohme LLC $2,030.00 1
INTUITIVE SURGICAL, INC. $790.68 7
ABBVIE INC. $99.11 3

Page 2 of 2; records 51–91 of 91 matching records. This page contains 41 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KARIM CHAMIE

NPI 1962478420 · CMS profile ID 133967

Allopathic & Osteopathic Physicians / Urology

LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–91 of 91 matching records. This page contains 41 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1962478420?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KARIM CHAMIE, NPI 1962478420, CMS profile ID 133967. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–91 of 91 matching records. This page contains 41 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1962478420?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). KARIM CHAMIE, NPI 1962478420, CMS profile ID 133967. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–91 of 91 matching records. This page contains 41 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1962478420?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
KARIM CHAMIE, NPI 1962478420, CMS profile ID 133967, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–91 of 91 matching records. This page contains 41 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1962478420?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

91 matching records · $120,518.62 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 91 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–91 of 91.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
UROGEN PHARMA, INC. $4,740.0005/29/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1244848990 CMS
UROGEN PHARMA, INC. $9,600.0005/29/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1244848992 CMS
Janssen Biotech, Inc. $881.2505/28/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1174690393 CMS
Astellas Pharma US Inc $136.6305/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238631637 CMS
Janssen Biotech, Inc. $1,410.0005/22/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1174667139 CMS
Janssen Biotech, Inc. $200.3705/22/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1174678065 CMS
Janssen Biotech, Inc. $140.8605/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174676236 CMS
Janssen Biotech, Inc. $4,582.5005/15/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1174677611 CMS
PFIZER INC. $1,000.0005/14/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1230583004 CMS
PFIZER INC. $1,500.0005/14/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1230626595 CMS
Janssen Biotech, Inc. $149.6505/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174675965 CMS
Janssen Biotech, Inc. $4,023.7505/09/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1174664805 CMS
UROGEN PHARMA, INC. $261.8005/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244847950 CMS
UROGEN PHARMA, INC. $106.8105/07/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1244847972 CMS
UROGEN PHARMA, INC. $527.4705/06/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1244847922 CMS
Janssen Biotech, Inc. $130.7004/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174686280 CMS
Janssen Biotech, Inc. $146.7504/23/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1174665953 CMS
Janssen Biotech, Inc. $19.0404/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174669539 CMS
Janssen Biotech, Inc. $42.5604/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174670513 CMS
Janssen Biotech, Inc. $152.7504/23/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1174683700 CMS
Janssen Biotech, Inc. $1,410.0004/21/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1174688538 CMS
Janssen Biotech, Inc. $222.8404/16/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1174679761 CMS
UROGEN PHARMA, INC. $1,422.9704/14/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1244830650 CMS
Janssen Biotech, Inc. $1,249.9203/04/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1174670125 CMS
INTUITIVE SURGICAL, INC. $58.8202/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236750023 CMS
Janssen Biotech, Inc. $705.0002/24/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1174670969 CMS
Janssen Biotech, Inc. $13,024.6202/21/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1174685361 CMS
Janssen Scientific Affairs, LLC $13,024.6202/21/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1174152053 CMS
Janssen Biotech, Inc. $120.9902/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174687088 CMS
Janssen Scientific Affairs, LLC $9.5702/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174151821 CMS
PFIZER INC. $149.1702/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230133265 CMS
INTUITIVE SURGICAL, INC. $91.6202/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236750009 CMS
INTUITIVE SURGICAL, INC. $46.5302/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236750013 CMS
ABBVIE INC. $29.8502/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201627158 CMS
Janssen Biotech, Inc. $22.3701/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174676593 CMS
Janssen Biotech, Inc. $7.6301/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174679665 CMS
Janssen Biotech, Inc. $62.3701/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174684162 CMS
Janssen Biotech, Inc. $122.8801/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174690628 CMS
INTUITIVE SURGICAL, INC. $131.1701/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236750026 CMS
INTUITIVE SURGICAL, INC. $16.0001/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236750031 CMS
INTUITIVE SURGICAL, INC. $316.6201/01/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1236750034 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $538.24 5
PY2020 $8,196.74 8
PY2021 $104,508.85 18
PY2022 $18,158.29 43
PY2023 $27,609.77 44
PY2024 $11,330.60 27
PY2025 $120,518.62 91

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,897,464.20 11
PY2024 Principal investigator $912,079.76 18
PY2023 Principal investigator $514,951.56 9
PY2022 Principal investigator $327,913.23 9
PY2021 Principal investigator $243,303.39 14
PY2020 Recipient $47,011.84 4
PY2020 Principal investigator $50,269.95 4
PY2019 Principal investigator $86,105.63 45

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

11 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $7,703.46 12/31/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 and Pembrolizumab in Combination with Other Investigational Agents in Subjects with High-risk Non-muscle-Invasive Bladder Cancer NMIBC Unresponsive to Bacillus Calmett No dispute reported 06/30/2026 1232925381
Principal investigator 1 Merck Sharp & Dohme LLC $64,473.39 12/31/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab MK-3475 Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer KEYNOTE-B15 , EV-304 No dispute reported 06/30/2026 1232927589
Principal investigator 1 Merck Sharp & Dohme LLC $993,315.37 12/31/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
STUDY NAME#Neoadjuvant Combination Pembrolizumab , Enfortumab Vedotin with Adjuvant Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Carcinoma No dispute reported 06/30/2026 1232932605
Principal investigator 1 Astellas US Technologies $235,956.00 11/25/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
Neoadjuvant Combination Pembrolizumab / Enfortumab Vedotin Prior to Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Carcinoma No dispute reported 06/30/2026 1214850764
Principal investigator 1 Merck Sharp & Dohme LLC $116,925.00 11/03/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab MK-3475 Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer KEYNOTE-B15 , EV-304 No dispute reported 06/30/2026 1232927545
Principal investigator 1 Astellas US Technologies $112,360.00 10/14/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
Neoadjuvant Combination Pembrolizumab / Enfortumab Vedotin Prior to Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Carcinoma No dispute reported 06/30/2026 1214850757
Principal investigator 1 Astellas Pharma Global Development $26,000.00 05/02/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
Neoadjuvant Combination Pembrolizumab / Enfortumab Vedotin Prior to Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Carcinoma No dispute reported 06/30/2026 1234180052
Principal investigator 1 Merck Sharp & Dohme LLC $47,689.98 05/01/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 and Pembrolizumab in Combination with Other Investigational Agents in Subjects with High-risk Non-muscle-Invasive Bladder Cancer NMIBC Unresponsive to Bacillus Calmett No dispute reported 06/30/2026 1232925205
Principal investigator 1 Astellas US Technologies $126,405.00 02/11/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
Neoadjuvant Combination Pembrolizumab / Enfortumab Vedotin Prior to Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Carcinoma No dispute reported 06/30/2026 1214850751
Principal investigator 1 PFIZER INC. $14,950.00 01/27/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A STUDY OF INTRAVESICAL ENFORTUMAB VEDOTIN FOR TREATMENT OF PATIENTS WITH NONMUSCLE INVASIVE BLADDER CANCER NMIBC No dispute reported 06/30/2026 1228859219
Principal investigator 1 Astellas US Technologies $151,686.00 01/20/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
Neoadjuvant Combination Pembrolizumab / Enfortumab Vedotin Prior to Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Carcinoma No dispute reported 06/30/2026 1214850745